Eisai Co., Ltd announced that it has received orphan drug designation for Lenvima (lenvatinib mesylate), the orally available multiple receptor kinase inhibitor discovered by Eisai, with a prospective ...
Eisai Co, Ltd and MSD K.K, a subsidiary of Merck & Co announced an application submission in Japan for the additional indication of Eisai’s in-house discovered and developed multiple receptor tyrosine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results